Furthermore, Pim kinase inhibitor M-110 was shown to reduce the expression of EGFR, leading to the reduction of extracellular signal-regulated kinase (ERK) pathway activity in prostate cancer (Siu et al., 2011). The gene discussed is EGFR; the disease is prostate cancer.